Clinical features and efficacy of escitalopram treatment for geriatric depression

Journal of International Medical Research

Volumn 39, Issue 5, 2011, Pages 1946-1953

  Chen, Y M ^a,b   Huang, X M ^b   Thompson, R ^b   Zhao, Y B ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Efficacy; Escitalopram; Geriatric Depression; Randomized Controlled Trial; Safety; Selective Serotonin Reuptake Inhibitor (SSRI)

Indexed keywords

ESCITALOPRAM; PLACEBO;

AGED; ARTICLE; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EYSENCK PERSONALITY QUESTIONNAIRE; FEMALE; GERIATRIC CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 80155141145     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900540     Document Type: Article

References (26)

1. Lapid MI, Rummans TA: Evaluation and management of geriatric depression in primary care. Mayo Clin Proc 2003; 78: 1423-1429.
2. Khouzam HR: The diagnosis and treatment of depression in the geriatric population. Compr Ther 2009; 35: 103-114.
3. Laks J, Engelhardt E: Peculiarities of geriatric psychiatry: a focus on aging and depression. CNS Neurosci Ther 2010; 16: 374-379.
4. Garnock-Jones KP, McCormack PL: Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs 2010; 9: 769-796.
5. American Psychiatric Association (APA): Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. Washington, DC: APA, 2000.
6. Yesavage JA, Brink TL, Rose TL, et al: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.
7. Sheikh JI, Yesavage JA, Brooks JO, et al: Proposed factor structure of the Geriatric Depression Scale. Int Psychogeriatr 1991; 3: 23-28.
8. Eysenck HJ, Eysenck SBG: Manual of the Eysenck Personality Questionnaire (Junior and Adult). London: Hodder and Stoughton, 1975.
9. Derogatis LR, Lipman RS, Covi L: SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull 1973; 9: 13-28.
10. Guy W, Clearly PA, Close JH, et al: ECDEU Assessment Manual for Psychopharmacology, DHEW publication (ADM) 76-338. Washington, DC: US Department of Health, Education, and Welfare, 1976.
11. Yang M, He TW, Zhu CM, et al: The use and analysis of Eysenck Personality Questionnaire in Chengdu, China. J Sichuan Univ Med Sci 1983; 2: 149-159 [in Chinese].
12. Jin H, Wu WY, Zhang MY: The use and analysis of SCL-90 in a normal Chinese population. Chin J Nerv Ment Dis 1986; 12: 260-263 [in Chinese].
13. Lebowitz BD, Pearson JL, Schneider LS, et al: Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997; 278: 1186-1190.
14. Heok KE, Ho R: The many faces of geriatric depression. Curr Opin Psychiatry 2008; 21: 540-545.
15. Beyer JL: Managing depression in geriatric populations. Ann Clin Psychiatry 2007; 19: 221-238.
16. Costello CG, Scott CB: Primary and secondary depression: a review. Can J Psychiatry 1991; 36: 210-217.
17. VanItallie TB: Subsyndromal depression in the elderly: underdiagnosed and undertreated. Metabolism 2005; 54(5 suppl 1): 39-44.
18. Hyttel J: Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9(suppl 1): 19-26.
19. Yang LP, Scott LJ: Escitalopram: in the treatment of major depressive disorder in adolescent patients. Paediatr Drugs 2010; 12: 155-163.
20. Höschl C, Svestka J: Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008; 8: 537-552.
21. Søgaard B, Mengel H, Rao N, et al: The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005; 45: 1400-1406.
22. Rao N: The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 4: 281-290.
23. Spina E, Santoro V, D'Arrigo C: Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206-1227.
24. Baldwin DS, Reines EH, Guiton C, et al: Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007; 10: 1583-1592.
25. Llorca PM, Fernandez JL: Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007; 61: 702-710.
26. Paul MA, Gray GW, Love RJ, et al: SSRI effects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects. Aviat Space Environ Med 2007; 78: 693-697.